Document is current

Article History

Received: 14 May 2025

Accepted: 27 November 2025

First Online: 15 December 2025

Competing interests

: Conflict of interest: F.N. personal fees from AstraZeneca, Accademia della Medicina, DOC CONGRESS SRL; travel grants from Merck.S.F.: Consulting or advisory board membership: Bayer, Illumina, Roche; honoraria: Amgen, Eli Lilly, PharmaMar, Roche; research funding: AstraZeneca, Pfizer, PharmaMar, Roche; travel or accommodation expenses: Amgen, Eli Lilly, Illumina, PharmaMar, Roche.F.d.B.: Consulting: BMS, Pierre Fabre, Mattioli 1885, MCCann Health, MSD, IQVIA, Novartis; Advisory arrangements: Tiziana Life Sciences, BMS, Celgene, Novartis, Servier, Pharm Research Associated, Daiichi Sankyo, Ignyta, Amgen, Pfizer, Octimet Oncology, Incyte, Pierre Fabre, Eli Lilly, Roche, AstraZeneca, Gentili, Dephaforum, Merck & Co., Kenilworth, NJ, Bayer, Fondazione Menarini, Sanofi, Incyte, Taiho; Speaker’s fees from BMS, Roche, Merck & Co., Kenilworth, NJ, Bayer, Ignyta, Dephaforum, Biotechespert, Prime Oncology, Pfizer, Nadirex, Ambrosetti, Incyte, Motore Sanità, Events, Fare Comunicazione, Itanet, Nadirex, ESO, AccMed, Idea-z; Grants/contracts: research, unrestricted, and/or travel: Novartis, Roche, BMS, Celgene, Incyte, NMS, the healthcare business of Merck KGaA, Darmstadt, Germany, Kymab, Pfizer, Tesaro, and Merck & Co., Kenilworth, NJ; Traveling expenses from Bristol Myers Squibb, Roche, Celgene, AmgenMN received Travel expenses for meetings from Astrazeneca, speaker honorarium from Accademia della Medicina and Incyte; honoraria from Sandoz, Medpoint SRL and Servier for editorial collaboration. Consultant honoraria from EMD Serono, Basilea Pharmaceutica, Servier, Incyte, MSD Italia, AstraZeneca, Taiho. All other authors declare no conflicts of interest.